The user discusses their hair loss experience, exploring various hypotheses including thyroid levels, vitamin D, DHEA, nutritional deficiency, diabetes, seborrheic dermatitis, lack of nutrition to hairfollicles, chronic inflammation, female pattern hair loss causes, cortisol, and prolactin levels. They are currently using finasteride, beta-sitosterol, and have tried topical dutasteride and microneedling therapy.
The conversation discusses starting Minoxidil for hair loss and suggests also using finasteride to prevent further balding. Minoxidil is expected to thicken current hair, but won't stop hairfollicles from dying.
User "Ant1pal" shares progress pictures of hair regrowth using Minoxidil, Estradiol valerate, and Spironolactone. Users discuss potential side effects and the possibility of localizing estrogen to hairfollicles for better treatment.
The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.
Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hairfollicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.
A trans woman is using 10 mg oral minoxidil, dutasteride, and estradiol for hair regrowth and is also doing dermastamping despite the pain. Users discuss the benefits of dermastamping for serum absorption and hairfollicle stimulation, with some expressing surprise at the high minoxidil dosage.
Verteporfin is discussed as a potential treatment for hair regrowth, but skepticism exists about its effectiveness in regenerating extracted hairfollicles. The conversation also mentions the possibility of needing a hair transplant by 2028.
PP-405, a potential hair loss treatment, shows promise in stimulating dormant hairfollicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.
The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.
The post discusses the theory that persistent dandruff in areas prone to hair loss could be a sign of hairfollicles dying due to DHT, indicating balding. The responses vary, with some users noting improvements in dandruff and hair loss with treatments like Dutasteride, while others experienced hair loss without dandruff.
CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgen receptors in hairfollicles, potentially offering fewer side effects.
First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hairfollicles, potentially reducing side effects.
A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.
A 24-year-old woman with thinning hair is using Minoxidil, saw palmetto, biotin, rosemary oil, and ketoconazole. She seeks advice on whether to try finasteride or dutasteride, the effects of Minoxidil shedding, and the significance of her hairfollicle condition.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
The user started using a hair loss treatment regimen including 5% minoxidil spray twice daily, 1% finasteride spray once daily, microneedling weekly, and ketoconazole shampoo twice a week, experiencing significant hair shedding. The shedding is seen as a positive sign, indicating hairfollicles are entering a new growth phase.
An 18-year-old with diffuse hair thinning is considering switching from a topical Minoxidil 10% + Finasteride 0.1% solution to Minoxidil 5% foam and oral Finasteride 0.5mg, while also addressing vitamin D deficiency and potential scalp inflammation. Users suggest using Nizoral shampoo for inflammation, considering dutasteride for better results, and maintaining vitamin D levels to protect hairfollicles from DHT.
A 31-year-old male experiencing hair thinning since age 25-26 uses minoxidil, finasteride, a red laser cap, and microneedling to promote hair growth. Users suggest reducing microneedling frequency to once a week to avoid damaging hairfollicles.
A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hairfollicles, rather than being purely hormonal.
Some individuals do not respond to oral minoxidil for hair loss, despite it generally working by improving blood flow to hairfollicles. Factors like metabolism, drug interactions, and individual variations in the drug's activation may influence its effectiveness.
GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hairfollicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.
The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hairfollicles instead of forming scars, providing an unlimited donor supply for hair transplants.
User asks if stacking Alfatradiol and Fluridil is effective for hair loss. Alfatradiol is a weaker, topical 5ar inhibitor, while Fluridil is an anti-androgen preventing DHT binding to hairfollicles.
A user shared their positive experience with Trichogenics for hair restoration, highlighting their unique zigzag hairline technique and personalized attention. They had 1700 follicles transplanted and praised the natural results.
The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.
OP injured their temple using derma rolling and tretinoin, causing peeling and potential hairfollicle damage. Users suggest the injury might be permanent, possibly resulting in scar tissue where hair won't grow.
The user shared a 3-month progress update on hair loss treatment using finasteride (1 mg), minoxidil (5% once or twice daily), and microneedling (1.5mm every 2 weeks) with no side effects. Commenters are impressed, discussing hairfollicle revival and the user's method, noting the hair appears darker.
The conversation discusses whether finasteride's reduction of DHT and increase in scalp testosterone contribute to hairfollicle miniaturization. Some participants argue testosterone does not cause miniaturization, while others suggest that even with reduced DHT, other androgens like testosterone may still contribute to hair loss.